当前位置: 首页 > 期刊 > 《右江医学》 > 202011
编号:13792658
华蟾素在泌尿系肿瘤中的治疗研究进展(5)
http://www.100md.com 2020年11月1日 《右江医学》 202011
     [18] KANG K H, HAN M H, JEONG J W, et al.Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis[J].Oncol Lett, 2017,14(1):853-859.

    [19] OCHOA C E, JOSEPH R W.Nivolumab in renal cell carcinoma:current trends and future perspectives[J].J Kidney Cancer VHL, 2018, 5(1):15-18.

    [20] RAVAUD A, MOTZER R J, PANDHA H S, et al.Adjuvant sunitinib in high risk renal cell carcinoma after nephrectomy[J].N Engl J Med, 2016,375(23):2246-2254.

    [21] XIANG R F, WANG Y, ZHANG N, et al.MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway[J].Cell Death Dis, 2017,8(5):e2776.

    [22] WANG C, WANG Q, LI X, et al.Lycorine induces apoptosis of bladder cancer T24 cells by inhibiting phospho-Akt and activating the intrinsic apoptotic cascade[J].Biochem Biophys Res Commun, 2017,483(1):197-202.

    [23] XIE J, LIN W, HUANG L, et al.Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway[J].Oncol Lett, 2018,16(3):3867-3873.

    [24] 王名琦,穆素紅.华蟾素抑制肾癌细胞786-O增殖及促凋亡作用研究[J].临床肾脏病杂志,2019,19(11):843-846.

    (收稿日期:2020-08-06 修回日期:2020-09-25)

    (编辑:潘明志), http://www.100md.com(吴潇芸 易楚繁 付伟金)
上一页1 2 3 4 5